title: Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.
authors.affiliation: Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Gasparotto
authors.affiliation: Treviso General Hospital, Pathology, Treviso, Italy.
authors.forename: Sabrina
authors.initials: S
authors.lastname: Rossi
authors.affiliation: San Giovanni Addolorata Hospital, Pathology, Rome, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Campagna
authors.affiliation: San Giovanni Addolorata Hospital, Oncology, Rome, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Scavina
authors.affiliation: Università Cattolica del Sacro Cuore, Istituto di Genetica Medica, Rome, Italy.
authors.forename: Francesco D
authors.initials: FD
authors.lastname: Tiziano
authors.affiliation: Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Marzotto
authors.affiliation: Treviso General Hospital, Pathology, Treviso, Italy.
authors.forename: Luisa
authors.initials: L
authors.lastname: Toffolatti
authors.affiliation: San Giovanni Addolorata Hospital, Surgery, Rome, Italy.
authors.forename: Carlo E
authors.initials: CE
authors.lastname: Vitelli
authors.affiliation: San Giovanni Addolorata Hospital, Pathology, Rome, Italy.
authors.forename: Mostafa
authors.initials: M
authors.lastname: Amini
authors.affiliation: Treviso General Hospital, Pathology, Treviso, Italy.
authors.forename: Angelo P
authors.initials: AP
authors.lastname: Dei Tos
authors.affiliation: Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy maestro@cro.it.
authors.forename: Roberta
authors.initials: R
authors.lastname: Maestro
mesh_terms: D034861:Abdominal Wall / Q000473:pathology; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D018095:Germ-Line Mutation; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000627:therapeutic use*; D009154:Mutation; D010235:Paraganglioma / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D012004:Rectal Neoplasms / Q000235:genetics* / Q000473:pathology; D013385:Succinate Dehydrogenase / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C491545:SDHD protein, human; D000068877:Imatinib Mesylate; D013385:Succinate Dehydrogenase; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha